Alonzo Weems - Eli Lilly VP Officer
| LLY Stock | MXN 13,339 869.50 6.97% |
Insider
Alonzo Weems is VP Officer of Eli Lilly and
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jennifer Mauer | Merck Company | N/A | |
| BCH BM | Bristol Myers Squibb | 57 | |
| David Williams | Merck Company | 54 | |
| Natacha Gassenbach | Biogen Inc | N/A | |
| Sandra Esq | Bristol Myers Squibb | 62 | |
| Susan Esq | Biogen Inc | 66 | |
| Giovanni MD | Bristol Myers Squibb | 58 | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| Lisa LeCointeCephas | Merck Company | 41 | |
| Nicole Murphy | Biogen Inc | N/A | |
| David Elkins | Bristol Myers Squibb | 55 | |
| Greg Meyers | Bristol Myers Squibb | 50 | |
| Peter Dannenbaum | Merck Company | N/A | |
| Michael Hencke | Biogen Inc | N/A | |
| Jitendra Tyagi | Bristol Myers Squibb | N/A | |
| Cristal Downing | Merck Company | 54 | |
| Michael CPA | Biogen Inc | 59 | |
| Caroline Litchfield | Merck Company | 54 | |
| Christopher Viehbacher | Biogen Inc | 63 | |
| Timothy Power | Bristol Myers Squibb | N/A | |
Management Performance
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Marram, Lead Independent Director | ||
| Kathi Seifert, Independent Director | ||
| Ralph Alvarez, Independent Director | ||
| Jamere Jackson, Independent Director | ||
| Joshua Smiley, CFO, Senior Vice President | ||
| Fionnuala Walsh, Senior Vice President - Global Quality | ||
| Johna Norton, Senior Vice President - Global Quality | ||
| Juan Luciano, Director | ||
| Alonzo Weems, VP Officer | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Anat Ashkenazi, VP CFO | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| John Lechleiter, Chairman, CEO and Pres | ||
| Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
| Karen Horn, Independent Director | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Darren Carroll, Senior Vice President - Corporate Business Development | ||
| William Kaelin, Director | ||
| Karen Walker, Director | ||
| Jacob Naarden, CEO VP | ||
| Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines | ||
| Barton Peterson, Senior Vice President - Corporate Affairs and Communications | ||
| Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | ||
| Enrique Conterno, Sr. VP and President of Lilly Diabetes | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Director | ||
| Michael Harrington, General Counsel and Sr. VP | ||
| David Hoover, Independent Director | ||
| Maria Crowe, President - Manufacturing Operations | ||
| Anat JD, Gen VP | ||
| Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research Laboratories | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories | ||
| Carolyn Bertozzi, Independent Director | ||
| Erik Fyrwald, Independent Director | ||
| Aarti Shah, Senior Vice President - Information Technology, and CIO | ||
| Susan Mahony, Senior Vice President and President - Lilly Oncology | ||
| Jackson Tai, Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Franklyn Prendergast, Independent Director |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 6.99 T | |||
| Shares Outstanding | 950.18 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 85.00 % | |||
| Price To Earning | 333.06 X | |||
| Price To Book | 34.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |